key: cord-0967406-0rlcc1wt authors: Patel, Kishan P.; Patel, Puja A.; Vunnam, Rama R.; Hewlett, Alexander T.; Jain, Rohit; Jing, Ran; Vunnam, Srinivas R. title: Gastrointestinal, Hepatobiliary, and Pancreatic Manifestations of COVID-19 date: 2020-04-29 journal: J Clin Virol DOI: 10.1016/j.jcv.2020.104386 sha: cdab2e02b9d99e4512484bec56e3a8277994d818 doc_id: 967406 cord_uid: 0rlcc1wt Abstract There is an increasing number of confirmed cases and deaths caused by the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contributing to the Coronavirus disease 2019 (COVID-19) pandemic. At this point, the need for further disease characterization is critical. COVID-19 is well established as a respiratory tract pathogen; however, recent studies have shown an increasing number of patients reporting gastrointestinal manifestations such as diarrhea, nausea, vomiting, and abdominal pain. The time from onset of gastrointestinal symptoms to hospital presentation is often delayed compared to that of respiratory symptoms. It has been noted that SARS-CoV-2 RNA can be detected in fecal matter for an extended period of time, even after respiratory samples have tested negative and patients are asymptomatic. In this article, SARS-CoV-2 and its disease COVID-19 will be reviewed with consideration of the latest literature about gastrointestinal symptomatology, the mechanisms by which the virus may inflict damage, and the possibility of viral replication contributing to a fecal-oral route of transmission. SARS-CoV-2 is an enveloped, non-segmented, positive-sense RNA virus responsible for the 2019 coronavirus disease (COVID-19) pandemic 1, 2 . To date, on April 17, 2020, there have been 2,074,529 confirmed cases and 139,378 deaths globally 3 . COVID-19 is rapidly transmissible, posing a considerable threat to global public health 4 . SARS-CoV-2 uses the receptor angiotensinconverting enzyme 2 (ACE2) to gain cellular entry into the lower respiratory tract of humans, which has also been noted to be highly expressed in gastrointestinal epithelial cells 1, 5 . Though patients typically endorse respiratory symptoms such as cough, dyspnea, and shortness of breath, there have been numerous reported cases of diagnosed COVID-19 patients exhibiting gastrointestinal manifestations such as diarrhea, nausea, vomiting, and abdominal pain 6, 7 . A study has shown that SARS-CoV-2 RNA can be detected in feces for up to a month in 83.3% of patients with a mild infection, raising suspicion for the gastrointestinal tract as an additional site of viral replication 8 . Additionally, another study demonstrated that out of 73 COVID-19 patients, 53.4% were found to have viral RNA present in their stool -23.3% of those patients had positive stool samples even after the viral RNA cleared from their respiratory tract 9 . As such, these characteristics have clinical implications regarding the proper management of infected individuals, a potential fecal-oral route of transmission, and effective preventative infection control. The most characterized symptoms of COVID-19 include fever, cough, fatigue, dyspnea, sore throat, headache, and myalgias or arthralgias 6 . Approximately 80% of patients demonstrate mild symptoms; 20% have severe disease; about 5% of patients exhibit critical disease symptoms such as respiratory arrest, septic shock, or multiple organ failure 6 . The median incubation period for COVID-19 is five days 10 . As SARS-CoV-2 has widely been studied as a respiratory tract pathogen, J o u r n a l P r e -p r o o f its extent of involvement in the gastrointestinal system is currently under investigation. A multicenter and cross-sectional study demonstrated that approximately 50% of patients experienced symptoms such as diarrhea, nausea, vomiting, abdominal pain. Similar studies in China supported the presence of these symptoms among COVID-19 patients (Table 1) 7, 11, 16, 17 . Furthermore, the time from onset of gastrointestinal symptoms to hospital presentation is delayed compared to respiratory symptoms (9.0 vs. 7.3 days) 11 . Additional studies have characterized similar results among COVID-19 patients. One study examining 651 patients in the Zhejiang Province of China showed that 11.4% presented with at least one gastrointestinal symptom consisting of nausea, vomiting, or diarrhea; the average age of these patients was 46.1 years, with 10.8% having pre-existing liver disease 7 . Of COVID-19 patients with gastrointestinal symptoms, a subset also experienced significantly higher rates of fever, fatigue, shortness of breath, and headache 7 . The first COVID-19 patient in the United States presented with nausea, vomiting, cough, with additional gastrointestinal symptoms of loose bowel movements and abdominal pain during his hospitalization. He eventually tested positive for SARS-CoV-2 RNA in his stool and respiratory specimens upon rRT-PCR testing 12, 13 . Additionally, the first case of hematochezia as a possible initial presenting symptom of COVID-19 was reported. Although the patient's stool specimens were not tested for viral RNA, this case highlights a rare gastrointestinal manifestation of the COVID-19 14 . Furthermore, other symptoms noted were anorexia (39.9%-50.2%), vomiting (3.6%-66.7%), nausea (1%-29.4%), abdominal pain (2.2%-6.0%), and gastrointestinal bleeding (4%-13.7%) 12 . Additional studies have characterized similar results amongst COVID-19 patients (see Table 2 ) 7, 11, [16] [17] [18] [19] [20] [21] [22] [23] [24] . It is crucial to note that adult and children patients with COVID-19 may present with digestive symptoms in the absence of respiratory symptomatology. The gastrointestinal manifestations secondary to SARS-CoV-2 infection can occur through different mechanisms. Firstly, ACE2 receptors, by which the virus uses to gain cellular entry, is expressed in both the respiratory tract and gastrointestinal tract epithelium, creating the potential for viral replication in the gastrointestinal tract. Secondly, there could be a direct injury of the gastrointestinal system due to an inflammatory response 11 . Absorptive enterocytes may be infected and destroyed by SARS-CoV-2, potentially leading to malabsorption, unbalanced intestinal secretion, and an activated enteric nervous system resulting in symptoms like diarrhea 15 . An increasing number of COVID-19 patients have been noted to experience hepatic injury, ranging on a spectrum of mild to severe damage 25 . Hepatic injury has been evident in specific laboratory abnormalities in these patientsthe pathophysiology behind SARS-CoV-2 infection may suggest the injury is due to the disease process. According to the American College of Gastroenterology (ACG), abnormal liver enzymes are observed in 20-30% of persons with confirmed COVID-19 infection 26 . In a study examining 148 confirmed SARS-CoV-2 infected patients in China, 50.7% of patients were found to have abnormal liver functions at admission 25 . Additional studies have demonstrated similar results with abnormalities in liver enzymes and total bilirubin ( Table 3) 11, 16, 18, [20] [21] [22] [23] 30, 31 . Patients with elevated liver function tests were more likely to have a moderate-high degree fever, and these elevations were significantly more prevalent in male patients (68.67% vs. 38.36%). Additionally, in these patients, the CD4+ and CD8+ T cells were substantially lower as compared to those with normal liver function tests 25 . Per the ACG, drops in leukocyte counts are observed in COVID-19 infection, and an elevated white blood cell count is considered a poor prognostic sign 26 . Studies have found that most liver injuries are mild and transient, but severe liver damage can also occur 27 . A higher magnitude of liver injury was noted in individuals with severe COVID-19, in which cases hepatoprotective drugs can be administered 5, 27 . The definitive mechanism by which liver injury occurs in COVID-19 patients is unclear. There are multiple theories of the pathophysiology of the viral infection that could explain this phenomenon: (1) ACE2-mediated direct viral infection of hepatocytes, (2) Critically-ill status and immune-mediated injury, or (3) Drug hepatotoxicity 5 . As it has been established that the receptor ACE2 by which SARS-CoV-2 uses to gain cellular entry is highly expressed in gastrointestinal epithelial cells, the virus could have the ability to infect cholangiocytes via this receptor to dysregulate liver function 1, 5 . Liver injury may also occur as ACE2 expression in liver tissue is upregulated as a compensatory proliferation of hepatocytes J o u r n a l P r e -p r o o f derived from bile duct epithelial cells 11 . While SARS-CoV-2 may cause dysregulation of hepatic function by binding directly to ACE2-receptor cholangiocytes, histological examination of a liver biopsy obtained from a deceased COVID-19 patient showed no viral inclusions, but rather microvesicular steatosis and mild lobular activity 27, 5 . Furthermore, in critically-ill COVID-19 patients, hepatocellular injury or even liver failure may be secondary to hypotension and immunemediated inflammation, such as cytokine storm or pneumonia-associated hypoxia 27 Antipyretics, which most of the patients in this study took prior to admission, could also cause drug-related pancreatic injury 32 . Further research is necessary to definitively determine the effect of SARS-CoV-2 on pancreatic function and regulation. SARS-CoV-2 can be found in the respiratory secretions of patients 1-2 days before onset of clinical symptoms and for up to two weeks after symptoms subside. The virus has previously been found in whole blood, serum, urine, and fecal samples 6 Accordingly, fecal-oral transmission must be taken into consideration. Of great significance is the fact that viral RNA in feces can remain even after viral RNA in the respiratory tract clearstherefore providing a potential source of spread. Considerations for testing of viral RNA in feces by rRT-PCR can be taken to monitor for adequate source and infection control 34 . Currently, nasopharyngeal samples are used for the testing of suspected COVID-19; however, with the occurrence of gastrointestinal manifestations, the use of fecal testing may be beneficial as well. Additionally, recognizing that gastrointestinal symptoms could be the initial presentation of COVID-19, prompt and timely diagnostic testing is necessary for early detection. Recognizing that the earliest presenting symptoms of COVID-19 could be gastrointestinal rather than respiratory may improve early detection with various available diagnostic tests. Extending beyond the usage of nasopharyngeal sample testing alone to include routine fecal RNA testing can be beneficial. Furthermore, identifying common laboratory abnormalities that these patients exhibit can also help in assessing the severity of the infection. To date, there is no specific antiviral treatment recommended for the treatment of COVID-19 nor is there a vaccine currently available, however clinical trials are in effect with medications such as J o u r n a l P r e -p r o o f lopinavir/ritonavir, chloroquine, hydroxychloroquine, aerosolized alpha-interferon, tocilizumab and remdesivir (an RNA polymerase inhibitor) 28 Additionally, laboratory abnormalities, hepatic injury, and pancreatic injury have been evident in a subset of patients, ranging on a spectrum with the severity of disease. As the viral receptor ACE2 is present in the gastrointestinal tract, it may play a role in the virus's ability to dysregulate the digestive system, hepatobiliary function, and pancreatic function, thereby resulting in gastrointestinal symptoms. Of note, a majority of the information presented in this narrative review was derived from reports originating from various regions in China. Consequently, application of these findings on a global scale is limited during an evolving pandemic. Likewise, the data displayed in our tables highlight variance among similar studies. As it has been shown that SARS-CoV-2 RNA can remain in stool longer than respiratory specimens, it may serve as evidence for gastrointestinal viral replication and subsequent shedding. Currently, while fecal-oral transmission has not been definitively proven, there is evidence to support its possibility, warranting the need for additional precautions. We did not receive any specific grant from funding agencies in the public, commercial, or not-forprofit sectors. The authors contributed to and reviewed all aspects of the article. https://www.asge.org/docs/default-source/default-document-library/press-release_impact-of-covid-19-on-endoscopy.pdf (2020). Table 3 : Percentage of COVID-19 patients exhibiting hepatobiliary laboratory abnormalities including AST, ALT, and total bilirubin in studies completed from China. 16 The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health Organization Coronavirus disease 2019 Coronavirus: A threat to Global Public Health Covid-19 and the Digestive System New Coronavirus: SARS-COV-2. Mucosa, 1-4 Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptomsGut Published Online First: 24 A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features Clinical Features of Stool SARS-CoV-2 RNA Positive Available at SSRN The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission First Case of 2019 Novel Coronavirus in the United States SARS-CoV-2 infection presenting with hematochezia. Médecine Et Maladies Infectieuses The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes Digestive manifestations in hospitalized patients with COVID-19: A single-center descriptive study Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan Clinical Characteristics of Coronavirus Disease 2019 in China Clinical Characteristics of 138 Hospitalized Patients With Novel Coronavirus-Infected Pneumonia in Wuhan, China Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study. The Lancet Respiratory Medicine Clinical Features of COVID-19 Related Liver Damage Joint GI Society Message on COVID-19. American College of Gastroenterology Liver injury in COVID-19: management and challenges Evaluation and Treatment Coronavirus (COVID-19). In: StatPearls [Internet Implications of COVID-19 for patients with pre-existing digestive diseases Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series Clinical features of patients infected with 2019 novel coronavirus in Wuhan Pancreatic injury patterns in patients with COVID-19 pneumonia Highly ACE2 Expression in Pancreas May Cause Pancreas Damage After SARS-CoV-2 Infection Evidence for Gastrointestinal Infection of SARS-CoV-2 None. The authors declare no competing interests.J o u r n a l P r e -p r o o f 81